FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247187552> ?p ?o ?g. }

• W2247187552 endingPage "138" @default.
• W2247187552 startingPage "138" @default.
• W2247187552 abstract "138 Background: AR-V7 is a truncated form of AR that lacks the ligand-binding domain but remains constitutively active. We previously showed that detection of AR-V7 from circulating tumor cells (CTCs) in men with mCRPC was associated with primary resistance to enzalutamide and abiraterone. Here, we hypothesized that AR-V7[+] patients would retain sensitivity to taxane chemotherapy. Methods: We used a qRT-PCR assay to interrogate CTCs for AR-V7 mRNA in prospectively enrolled patients with mCRPC starting docetaxel or cabazitaxel. We sought associations between AR-V7 status and PSA response rates (the primary endpoint), PSA progression-free survival (PSA-PFS), and clinical/radiographic progression-free survival (PFS). Multivariable regressions were performed to determine the independent effect of AR-V7 status on clinical outcomes. 36 taxane-treated men were required to produce a 2-sided 95% CI for the difference in PSA response rates (between AR-V7[+] and AR-V7[–] men) with an upper bound of 60%, assuming that 30% of men would be AR-V7[+]. Results: 37 taxane-treated patients were enrolled, and 17 (45.9%) had detectable AR-V7 in CTCs. PSA responses were achieved in both AR-V7[+] and AR-V7[–] men (41% vs 65%, P=0.19). Median PSA-PFS was comparable in AR-V7[+] and AR-V7[–] men (4.5 vs 6.2 mo, HR 1.72, P=0.32). Likewise, median PFS was comparable in AR-V7[+] and AR-V7[–] men (5.1 vs 6.9 mo, HR 2.65, P=0.11). After incorporating data from our prior study in 62 abi/enza-treated patients, it was observed that clinical outcomes in AR-V7[+] men were superior with taxanes than with abi/enza, while outcomes did not differ by treatment type in AR-V7[–] men. For example, in AR-V7[+] men, PSA responses were higher in taxane-treated versus abi/enza-treated men (41% vs 0%, P<0.001), and median PSA-PFS and PFS were longer in taxane-treated men (HR for PSA-PFS = 0.19, P=0.001; HR for PFS = 0.21, P=0.003). Conclusions: Detection of AR-V7 in CTCs from men with mCRPC is not associated with primary resistance to taxane chemotherapy, and such patients may retain sensitivity to taxanes. Further, in AR-V7[+] men, taxanes appear to be more efficacious than abi/enza. AR-V7 may represent a treatment-selection marker in mCRPC." @default.
• W2247187552 created "2016-06-24" @default.
• W2247187552 creator A5001771354 @default.
• W2247187552 creator A5001783218 @default.
• W2247187552 creator A5009105768 @default.
• W2247187552 creator A5012074439 @default.
• W2247187552 creator A5025251109 @default.
• W2247187552 creator A5036072908 @default.
• W2247187552 creator A5037458498 @default.
• W2247187552 creator A5057048206 @default.
• W2247187552 creator A5068348417 @default.
• W2247187552 creator A5075880342 @default.
• W2247187552 creator A5080102032 @default.
• W2247187552 creator A5083333223 @default.
• W2247187552 creator A5088048189 @default.
• W2247187552 creator A5088435494 @default.
• W2247187552 date "2015-03-01" @default.
• W2247187552 modified "2023-09-23" @default.
• W2247187552 title "AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC)." @default.
• W2247187552 doi "https://doi.org/10.1200/jco.2015.33.7_suppl.138" @default.
• W2247187552 hasPublicationYear "2015" @default.
• W2247187552 type Work @default.
• W2247187552 sameAs 2247187552 @default.
• W2247187552 citedByCount "14" @default.
• W2247187552 countsByYear W22471875522015 @default.
• W2247187552 countsByYear W22471875522016 @default.
• W2247187552 countsByYear W22471875522017 @default.
• W2247187552 crossrefType "journal-article" @default.
• W2247187552 hasAuthorship W2247187552A5001771354 @default.
• W2247187552 hasAuthorship W2247187552A5001783218 @default.
• W2247187552 hasAuthorship W2247187552A5009105768 @default.
• W2247187552 hasAuthorship W2247187552A5012074439 @default.
• W2247187552 hasAuthorship W2247187552A5025251109 @default.
• W2247187552 hasAuthorship W2247187552A5036072908 @default.
• W2247187552 hasAuthorship W2247187552A5037458498 @default.
• W2247187552 hasAuthorship W2247187552A5057048206 @default.
• W2247187552 hasAuthorship W2247187552A5068348417 @default.
• W2247187552 hasAuthorship W2247187552A5075880342 @default.
• W2247187552 hasAuthorship W2247187552A5080102032 @default.
• W2247187552 hasAuthorship W2247187552A5083333223 @default.
• W2247187552 hasAuthorship W2247187552A5088048189 @default.
• W2247187552 hasAuthorship W2247187552A5088435494 @default.
• W2247187552 hasConcept C121608353 @default.
• W2247187552 hasConcept C126322002 @default.
• W2247187552 hasConcept C143998085 @default.
• W2247187552 hasConcept C2776551883 @default.
• W2247187552 hasConcept C2777511904 @default.
• W2247187552 hasConcept C2777899217 @default.
• W2247187552 hasConcept C2778971682 @default.
• W2247187552 hasConcept C2779013556 @default.
• W2247187552 hasConcept C2780192828 @default.
• W2247187552 hasConcept C2781190966 @default.
• W2247187552 hasConcept C530470458 @default.
• W2247187552 hasConcept C61238886 @default.
• W2247187552 hasConcept C61367390 @default.
• W2247187552 hasConcept C71924100 @default.
• W2247187552 hasConceptScore W2247187552C121608353 @default.
• W2247187552 hasConceptScore W2247187552C126322002 @default.
• W2247187552 hasConceptScore W2247187552C143998085 @default.
• W2247187552 hasConceptScore W2247187552C2776551883 @default.
• W2247187552 hasConceptScore W2247187552C2777511904 @default.
• W2247187552 hasConceptScore W2247187552C2777899217 @default.
• W2247187552 hasConceptScore W2247187552C2778971682 @default.
• W2247187552 hasConceptScore W2247187552C2779013556 @default.
• W2247187552 hasConceptScore W2247187552C2780192828 @default.
• W2247187552 hasConceptScore W2247187552C2781190966 @default.
• W2247187552 hasConceptScore W2247187552C530470458 @default.
• W2247187552 hasConceptScore W2247187552C61238886 @default.
• W2247187552 hasConceptScore W2247187552C61367390 @default.
• W2247187552 hasConceptScore W2247187552C71924100 @default.
• W2247187552 hasIssue "7_suppl" @default.
• W2247187552 hasLocation W22471875521 @default.
• W2247187552 hasOpenAccess W2247187552 @default.
• W2247187552 hasPrimaryLocation W22471875521 @default.
• W2247187552 hasRelatedWork W122177069 @default.
• W2247187552 hasRelatedWork W2094570582 @default.
• W2247187552 hasRelatedWork W2135620818 @default.
• W2247187552 hasRelatedWork W2305036325 @default.
• W2247187552 hasRelatedWork W2568045406 @default.
• W2247187552 hasRelatedWork W2735900144 @default.
• W2247187552 hasRelatedWork W2776356588 @default.
• W2247187552 hasRelatedWork W2783882412 @default.
• W2247187552 hasRelatedWork W2901274396 @default.
• W2247187552 hasRelatedWork W2953010053 @default.
• W2247187552 hasVolume "33" @default.
• W2247187552 isParatext "false" @default.
• W2247187552 isRetracted "false" @default.
• W2247187552 magId "2247187552" @default.
• W2247187552 workType "article" @default.